$XBIT
XBiotech Inc.

2019 Q2 Form 10-Q Financial Statement

#000117184319003199 Filed on May 09, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $1.310M $1.280M $1.160M
YoY Change -21.56% 10.34% -44.23%
% of Gross Profit
Research & Development $4.693M $4.527M $2.993M
YoY Change 18.84% 51.25% -63.45%
% of Gross Profit
Depreciation & Amortization $600.0K $602.0K $588.0K
YoY Change -1.64% 2.38% 98.65%
% of Gross Profit
Operating Expenses $6.006M $5.805M $4.150M
YoY Change 6.85% 39.88% -59.59%
Operating Profit -$6.006M -$5.805M -$4.150M
YoY Change 6.85% 39.88% -59.59%
Interest Expense $150.0K -$70.00K $80.00K
YoY Change -151.72% -187.5% -127.59%
% of Operating Profit
Other Income/Expense, Net $154.0K -$59.00K $81.00K
YoY Change -153.85% -172.84% -127.74%
Pretax Income -$5.852M -$5.864M -$4.070M
YoY Change -0.98% 44.08% -61.46%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.852M -$5.864M -$4.069M
YoY Change -0.93% 44.11% -61.48%
Net Earnings / Revenue
Basic Earnings Per Share -$0.16 -$0.16
Diluted Earnings Per Share -$0.16 -$0.16 -$114.8K
COMMON SHARES
Basic Shares Outstanding 36.11M 36.05M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.90M $12.00M $28.40M
YoY Change 81.05% -57.75% -47.99%
Cash & Equivalents $44.92M $12.02M $28.42M
Short-Term Investments
Other Short-Term Assets $700.0K $1.000M $1.300M
YoY Change -22.22% -23.08% -48.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $45.60M $12.98M $29.75M
YoY Change 76.97% -56.36% -47.89%
LONG-TERM ASSETS
Property, Plant & Equipment $26.28M $26.84M $29.11M
YoY Change -7.88% -7.79% -4.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $26.28M $26.84M $29.11M
YoY Change -7.88% -7.79% -4.65%
TOTAL ASSETS
Total Short-Term Assets $45.60M $12.98M $29.75M
Total Long-Term Assets $26.28M $26.84M $29.11M
Total Assets $71.88M $39.82M $58.86M
YoY Change 32.39% -32.34% -32.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.550M $1.861M $1.160M
YoY Change 6.53% 60.43% -56.99%
Accrued Expenses $912.0K $980.0K $1.274M
YoY Change -29.9% -23.08% -51.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.462M $2.841M $2.434M
YoY Change -10.67% 16.72% -54.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.462M $2.841M $2.434M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.462M $2.841M $2.450M
YoY Change -11.05% 15.96% -54.17%
SHAREHOLDERS EQUITY
Retained Earnings -$249.4M -$243.6M -$220.6M
YoY Change 10.1% 10.39% 13.74%
Common Stock $319.0M $280.7M $277.8M
YoY Change 14.58% 1.03% 0.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $69.41M $36.98M $56.41M
YoY Change
Total Liabilities & Shareholders Equity $71.88M $39.82M $58.86M
YoY Change 32.39% -32.34% -32.82%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$5.852M -$5.864M -$4.069M
YoY Change -0.93% 44.11% -61.48%
Depreciation, Depletion And Amortization $600.0K $602.0K $588.0K
YoY Change -1.64% 2.38% 98.65%
Cash From Operating Activities -$4.860M -$4.677M -$3.526M
YoY Change 24.62% 32.64% -70.39%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $6.000K $34.00K
YoY Change -40.0% -82.35% -94.4%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K -$6.000K -$34.00K
YoY Change -40.0% -82.35% -94.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 37.90M 741.0K 201.0K
YoY Change 268.66% -99.39%
NET CHANGE
Cash From Operating Activities -4.860M -4.677M -3.526M
Cash From Investing Activities -30.00K -6.000K -34.00K
Cash From Financing Activities 37.90M 741.0K 201.0K
Net Change In Cash 33.01M -3.942M -3.359M
YoY Change -935.7% 17.36% -116.63%
FREE CASH FLOW
Cash From Operating Activities -$4.860M -$4.677M -$3.526M
Capital Expenditures -$30.00K $6.000K $34.00K
Free Cash Flow -$4.830M -$4.683M -$3.560M
YoY Change 25.45% 31.54% -71.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36113175
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1861000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1653000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
980000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1291000
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-117000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-255000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
570000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
110000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
570000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
110000
CY2019Q1 us-gaap Assets
Assets
39824000
CY2018Q4 us-gaap Assets
Assets
44345000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
12982000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
17016000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
109000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
25000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15823000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31768000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12019000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28416000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3804000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3352000
CY2019Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2018Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2019Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2018 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36090125
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38899772
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
280664000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
279353000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5726000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4062000
CY2019Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> financial institution. These amounts at times <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any credit losses in such accounts and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe it is exposed to any significant credit risk on these funds. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div></div></div></div></div></div>
CY2019Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3000
CY2019Q1 us-gaap Depreciation
Depreciation
602000
CY2018Q1 us-gaap Depreciation
Depreciation
588000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
138000
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
7000
CY2019Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-146000
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
17000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1278000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1157000
CY2019Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
99000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-596000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-311000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
212000
CY2019Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-3000
CY2018Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-3000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-230000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-232000
CY2019Q1 us-gaap Investment Income Net
InvestmentIncomeNet
78000
CY2018Q1 us-gaap Investment Income Net
InvestmentIncomeNet
64000
CY2019Q1 us-gaap Liabilities
Liabilities
2841000
CY2018Q4 us-gaap Liabilities
Liabilities
2947000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39824000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44345000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2841000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2944000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
741000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
201000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4677000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3526000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5864000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-4069000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-59000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
81000
CY2019Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
5805000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
4150000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5805000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4150000
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
138000
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
CY2019Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
9000
CY2018Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34000
CY2019Q1 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2018Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2019Q1 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2018 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
963000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1193000
CY2019Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
541000
CY2018Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
201000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
401000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
643000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26842000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27329000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4527000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2993000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-243564000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237700000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
570000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
110000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
126875
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
215000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.92
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.02
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5535439
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5432661
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.50
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
161000
CY2019Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
190903
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
643000
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
201000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
41398000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
36983000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
60162000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
56410000
CY2018Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
200000
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Use of Estimates </div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.</div></div></div></div></div></div>
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35977422
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35447304
CY2019Q1 xbit Common Stock Share Subscribed Value Issuance
CommonStockShareSubscribedValueIssuance
-102000
CY2019Q1 xbit Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
200000
CY2018Q1 xbit Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
CY2019Q1 xbit Stock Issued During Period Value Collection Of Stock Subscription
StockIssuedDuringPeriodValueCollectionOfStockSubscription
200000
CY2019Q1 xbit Subscription Receivable
SubscriptionReceivable
102000
CY2018Q1 xbit Subscription Receivable
SubscriptionReceivable

Files In Submission

Name View Source Status
0001171843-19-003199-index-headers.html Edgar Link pending
0001171843-19-003199-index.html Edgar Link pending
0001171843-19-003199.txt Edgar Link pending
0001171843-19-003199-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_050919p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbit-20190331.xml Edgar Link completed
xbit-20190331.xsd Edgar Link pending
xbit-20190331_cal.xml Edgar Link unprocessable
xbit-20190331_def.xml Edgar Link unprocessable
xbit-20190331_lab.xml Edgar Link unprocessable
xbit-20190331_pre.xml Edgar Link unprocessable